How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relievednews2024-11-25T21:12:39+00:00November 25th, 2024|Endpoints News|
#ASH24: Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDAnews2024-11-25T16:36:01+00:00November 25th, 2024|Endpoints News|
Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trialnews2024-11-25T16:28:37+00:00November 25th, 2024|Endpoints News|
Biohaven’s myostatin inhibitor misses primary endpoint in spinal muscular atrophy trialnews2024-11-25T16:12:43+00:00November 25th, 2024|Endpoints News|
AstraZeneca’s Truqap edges closer to prostate cancer label expansion with Phase 3 winnews2024-11-25T11:57:13+00:00November 25th, 2024|Endpoints News|
Patient dies in Neurogene’s Rett syndrome studynews2024-11-21T22:30:12+00:00November 21st, 2024|Endpoints News|
AstraZeneca culls Phase 2 opioid use disorder drugnews2024-11-21T20:54:54+00:00November 21st, 2024|Endpoints News|
Aizen debuts with AI-driven ‘mirror peptide’ platformnews2024-11-21T11:26:10+00:00November 21st, 2024|Endpoints News|
Novartis buys Kate Therapeutics in $1.1B deal, eyes more bolt-on M&Anews2024-11-21T11:10:58+00:00November 21st, 2024|Endpoints News|
NewAmsterdam aces Phase 3 trial, but investors are skepticalnews2024-11-20T21:18:34+00:00November 20th, 2024|Endpoints News|
